Status:
COMPLETED
Study of Paxil Use in Menopausal Women
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Menopause
Eligibility:
FEMALE
40+ years
Phase:
PHASE4
Brief Summary
To evaluate the efficacy, safety, and tolerability of Paroxetine treatment in perimenopausal and postmenopausal women who present with menopause-related symptoms after discontinuing hormone therapy (H...
Detailed Description
This study is a 10-week double-blinded treatment study of perimenopausal and postmenopausal women who present with menopause-related symptoms after discontinuing Hormone Therapy(HT), with or without c...
Eligibility Criteria
Inclusion
- Women age 40 and above.
- Perimenopausal status (defined as having cycles which vary by more than 7 days from normal, or 2 or more skipped cycles and an amenorrheic interval of at least 60 days but no more than 12 consecutive months) or postmenopausal status (defined as amenorrheic for 12 or more consecutive months).
- Women with prior use of HT for at least two months.
- Women who discontinued HT use 1 to 12 months prior to study entry (screening visit).
- Women who present with significant menopause-related symptoms (defined as GCS total score \>20; vasomotor sub-scores \>3 and/or ³14 moderate to severe hot flashes per week), with or without concomitant psychological complaints (symptoms of depression and/or anxiety).
- Women who report physical/emotional symptoms developing or worsening within 3 months of HT discontinuation.
- General good health.
Exclusion
- Women who present with moderate-to-severe symptoms of depression (MADRS scores \> 19) or anxiety (BAI scores \> 19) at baseline.
- Women who meet diagnostic criteria at screening visit for a current major Axis I psychiatric disorder other than specific phobias (assessed through M.I.N.I. interview). Subjects presenting with symptoms of anxiety or depression, but not meeting criteria for Depressive Disorders, Bipolar Disorder, Panic Disorder, GAD, OCD or SAD, will be allowed in the study.
- Regular treatment with hormonal medications, SSRIs, tricyclic antidepressant, mood stabilizer, oral neuroleptics, sedatives or hypnotics, over-the-counter agents known to influence hot flushes or mood within 4 weeks prior to screening visit; used of depot neuroleptics within 12 weeks prior to screening visit.
- Suicidal ideation, homicidal ideation, or psychotic symptoms.
- Menstrual dysfunction and amenorrhea of other etiologies.
- History of seizure disorder
- Pregnancy or breastfeeding.
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT00225914
Start Date
September 1 2004
End Date
September 1 2006
Last Update
November 24 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MGH Center for Perinatal and Women's Mental Health
Boston, Massachusetts, United States, 02116